By 2022, the French pharmaceutical company Sanofi intends to allocate its business of manufacturing active pharmaceutical ingredients (AFS) as a separate business. Currently being prepared for listing on the stock exchange, reports Reuters.
In December 2019 Executive Director of Sanofi Paul Hudson presented a plan to increase company revenues by 2022. Among other things it was proposed to complete the development of drugs for the treatment of diabetes and cardiovascular disease, reduce costs, and to allocate the production of AFS as a separate business.
According to forecasts, the new company will amount to 1-2 billion euros. The business will include the production site of Sanofi in France, Italy, Germany, UK and Hungary.